文献速递主动脉疾病

JOTEC髂分支装置用于排除臀下动脉瘤:ABRAHAM研究

The JOTEC iliac branch device for exclusion of hypogastric artery aneurysms: ABRAHAM study.
PubMed 文献 · J Vasc Surg · 2019-03-06

该回顾性研究纳入14例男性患者(76±4岁),共植入18个JOTEC髂分支装置(IBD)治疗臀下动脉瘤(HAA)。技术成功率100%,随访19±11个月,临床成功率和通畅率均为100%,IBD相关死亡率为0%,但需注意内漏及再干预。

要点

  • IBD治疗HAA的早期和中期结果良好,技术成功率与通畅率均达100%。
  • 充分封闭臀下动脉锚定区及侧支闭塞对预防IB型和II型内漏至关重要。
  • 随访期间再干预率较高,2.7年免于再干预率仅31%±23%。

核心结论

  • IBD用于HAA的早期和中期结果良好,临床成功率和通畅率均为100%,IBD相关死亡率为0%。

研究设计与样本

  • 回顾性分析2012年1月1日至2018年3月1日在本中心因HAA接受IBD治疗的患者,排除标准包括无HA受累、急诊手术及未使用IBD的HA支架移植。
  • 共纳入14例男性患者(年龄76±4岁,范围70-83岁),植入18个IBD(单纯IBD 4个,IBD+EVAR 7个,IBD±EVAR+侧支闭塞7个)。

主要发现

  • 无术中并发症,技术成功率为100%。
  • 随访19±11个月(范围2-39个月),2例杂交再干预(髂外动脉闭塞1例,EVAR移植物扭结1例)和4例血管腔内再干预(2例IB型内漏行侧支弹簧圈栓塞+支架移植延伸,2例IIIB型内漏行支架移植)。
  • 1例IBD相关II型内漏随访期间瘤径稳定,1例小IB型内漏自限。
  • 估计2.7年免于再干预率为31%±23%,临床成功率和通畅率均为100%,IBD相关死亡率为0%。

关键数值与推荐

  • 技术成功定义为无术中并发症且成功植入IBD,本研究为100%。
  • 临床成功和通畅率均为100%,IBD相关死亡率为0%。
  • 估计2.7年免于再干预率为31%±23%。

临床怎么用

  • 对于HAA患者,IBD是一种可行的血管腔内治疗选择,但需严格掌握适应证并注意锚定区密封和侧支闭塞以预防内漏。
  • 术后需密切随访监测内漏和再干预,尤其关注IB型和II型内漏的发生。

局限性

  • 回顾性研究,样本量小(14例患者,18个IBD),随访时间有限(19±11个月)。
  • 仅纳入男性患者,结果可能不适用于女性。
  • 未报告与其他治疗方式的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypogastric artery aneurysms (HAAs) are rare but life-threatening in cases of rupture. Open or endovascular techniques traditionally aimed at occluding the hypogastric artery (HA) have considerable risk of pelvic ischemia. Iliac branch devices (IBDs) are indicated for aortoiliac aneurysms; however, they have also been used lately for HAAs. Currently, there are no reports about patient outcomes focusing on HAA therapy using IBDs. We retrospectively analyzed early and midterm outcomes using IBDs for HAAs. METHODS: Patients who received IBDs for HAAs at our department from January 1, 2012, through March 1, 2018, were included. Exclusion criteria were as follows: no HA involvement, emergency procedures, and HA stent grafting without IBD. Perioperative and follow-up data were collected from medical records. RESULTS: There were 18 IBDs (only IBD, n = 4; IBD + endovascular aneurysm repair [EVAR], n = 7; IBD ± EVAR + side branch occlusion, n = 7) implanted into 14 male patients (76 ± 4 [70-83] years). There were no intraoperative complications, and the technical success rate was 100%. After 19 ± 11 (2-39) months of follow-up, two hybrid (external iliac artery occlusion, n = 1; EVAR graft kinking, n = 1) and four endovascular reinterventions due to two type IB (side branch coiling + stent graft extension) and two type IIIB (stent grafting) endoleaks were required. One IBD-related type II endoleak revealed constant aneurysm diameters during follow-up. One small type IB endoleak was self-limited. Estimated freedom from reintervention was 31% ± 23% at 2.7 years. The clinical success and patency rate was 100%. The IBD-related mortality was 0%. CONCLUSIONS: The IBD for HAA shows good early and midterm results. Adequate sealing of HA landing zones and side branch occlusion are technically challenging but crucial to prevent type IB and type II endoleaks.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dueppers P, Duran M, Floros N, et al. The JOTEC iliac branch device for exclusion of hypogastric artery aneurysms: ABRAHAM study. J Vasc Surg. 2019. PMID: 30850288. doi:10.1016/j.jvs.2018.10.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。